These agents have been particularly useful for elderly patients and those with comorbidities, who do not tolerate chemoimmunotherapy as well, and also for patients with higher risk forms of CLL, such as those with TP53 aberrant disease, who do not typically respond durably to chemoimmunotherapy. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.